This Analyst Believes Seagen Is Evaluating Strategic Alternatives
This Analyst Believes Seagen Is Evaluating Strategic Alternatives
這位分析師認為,西根正在評估戰略選擇
- Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price.
- Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company.
- The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent and limited existing antibody-drug conjugate exposure, Merck could be seen as a viable bidder.
- Related: Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ
- The biggest counterpoint to a potential buyout of Seagen is the cluster of potential patent expiry around 2030. The analysts estimate peak sales of ~$6.7 billion in 2030 but are likely below internal risk-modeled assessments.
- "Overall, the expected growth of the existing Seagen commercial portfolio, significant optionality of label expansion for key programs such as PADCEV, and general increased interest in the ADC modality post-DestinyBreast-04, will likely support Seagen as a high-interest candidate," notes Raymond James.
- Price Action: SGEN shares are down 0.15% at $178.40 during the market session on the last check Wednesday.
- Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price.
- Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company.
- The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent and limited existing antibody-drug conjugate exposure, Merck could be seen as a viable bidder.
- Related: Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ
- The biggest counterpoint to a potential buyout of Seagen is the cluster of potential patent expiry around 2030. The analysts estimate peak sales of ~$6.7 billion in 2030 but are likely below internal risk-modeled assessments.
- "Overall, the expected growth of the existing Seagen commercial portfolio, significant optionality of label expansion for key programs such as PADCEV, and general increased interest in the ADC modality post-DestinyBreast-04, will likely support Seagen as a high-interest candidate," notes Raymond James.
- Price Action: SGEN shares are down 0.15% at $178.40 during the market session on the last check Wednesday.
- 雷蒙德·詹姆斯在以下日期開始覆蓋SeaGen公司(納斯達克:SGEN)強於大盤,目標價為220美元。
- 雷蒙德·詹姆斯認為,董事會可能正在評估公司的戰略選擇,理由是長期擔任Seagen首席執行官的雷蒙德·詹姆斯最近離職了。
- 與中國的關係默克公司(紐約證券交易所代碼:MRK)由來已久。隨着Keytruda失去專利,並限制現有的抗體-藥物結合物暴露,默克可以被視為一個可行的競購者。
- 相關:默克/Seagen潛在交易談判提速:《華爾街日報》
- 對Seagen的潛在收購最大的對立面是2030年左右到期的一系列潛在專利。分析師估計,2030年的峯值銷售額約為67億美元,但可能低於內部風險模型評估。
- 雷蒙德·詹姆斯指出:“總體而言,現有Seagen商業產品組合的預期增長、PADCEV等關鍵項目標籤擴展的顯著可選性,以及DestinyBreast-04之後人們對ADC模式的普遍興趣增加,可能會支持Seagen成為一個高興趣的候選者。”
- 價格行動:截至週三尾盤,Sgen股價下跌0.15%,至178.40美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!